A5050161310- RNA modifications and cancer
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- RNA and protein synthesis mechanisms
- RNA regulation and disease
- CRISPR and Genetic Engineering
- Acute Myeloid Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Viral-associated cancers and disorders
- Single-cell and spatial transcriptomics
- Immune cells in cancer
- Cancer-related molecular mechanisms research
University of Chinese Academy of Sciences
2019-2023
Beijing Institute of Genomics
2018-2023
Chinese Academy of Sciences
2018-2023
Sino-Danish Centre for Education and Research
2018-2021
A new layer of transcriptional control N 6 -methyladenosine (m A) is the most abundant messenger RNA modification in almost all eukaryotes. Liu et al. now show that m also cotranscriptionally added onto various chromosome-associated regulatory RNAs (carRNAs) mammalian cells. Disruption these increases their abundance and promotes gene transcription by increasing chromatin accessibility. Thus, serves as a switch to regulate carRNA levels tuning nearby state downstream transcription. Science ,...
CRISPR-Cas12a/Cpf1, a single RNA-guided endonuclease system, provides promising tool for genome engineering. However, only three Cas12a orthologs have been employed mammalian editing, and the editing efficiency as well targeting coverage still requires improvements. Here, we harness six novel in human mouse cells, some of which utilize simple protospacer adjacent motifs (PAMs) that remarkably increase range genomes. Moreover, identify optimized CRISPR RNA (crRNA) scaffolds can Cas12a.
The base editor pnCasSA-BEC enables highly efficient editing in <italic>Staphylococcus aureus</italic>.
Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients high-risk acute myeloid leukemia (AML). However, biological factors driving the therapeutic response of such hypomethylating (HMA)-based therapies remain unknown. Herein, transcriptome and/or genome-wide 5-hydroxymethylcytosine (5hmC) characterized 41 AML from phase 1 clinical trial treated AZA priming followed by high-dose cytarabine...